Where Diabetes and Technology meet
Search the app stores for diabetes and AI and you will find a remarkable number of applications doing exactly one thing. You point a camera [...] The post A world of pure imagination: AI, diabetes and the data we can’t get at first appeared on Diabettech - Diabetes and Technology .
A slightly rhetorical question, I ll admit, but a pertinent one. Once again, I have been trying out the latest (read most heavily pushed on Facebook [...] The post Why is the cheese sandwich the downfall of AI carb counting, even with “3D scanning”? first appeared on Diabettech - Diabetes and Technology .
Abbott has put glucose and ketones on the same wearable, and the launch coverage is all about DKA. Worth having if you’re on a pump, which is fine as far as it goes, but it misses the bit that makes this interesting. Because if you look at what Abbott has actually built across its other divisions, and what they’ve patented alongside it, the Libre Duo doesn’t really look like a ketone sensor. It…
We took Nightscout data from three people and gave it to 5 Large Language Models with a detailed prompt to see how they would respond. The results weren't what I was expecting. The post Five AI models, three users, one finding: the settings came from the textbook, not the data first appeared on Diabettech - Diabetes and Technology .
Ask ChatGPT to estimate the carbs in your lunch. Now ask it again. And again. Five hundred times. You’d expect the same answer each time. [...] The post I Asked AI to Count My Carbs 27,000 Times. It Couldn’t Give Me the Same Answer Twice. first appeared on Diabettech - Diabetes and Technology .
Welcome to today s edition of The Daily Bolus! The incretin landscape is rapidly evolving into the era of the triple agonist, with Eli Lilly and [...] The post The Daily Bolus: The Triple Agonist Showdown & Surprising GLP-1 Wins in Type 1 Diabetes first appeared on Diabettech - Diabetes and Technology .
Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn't it a cure yet, and how does it fit into the actual blueprint of a functional cure? The post 100% Insulin Independence: Why Eledon’s…
After 10+ years of documenting the diabetes landscape, Diabettech is launching diabettech.ai—a custom research tool designed to help you navigate a decade’s worth of articles and reports. Powered by an LLM interface, this tool allows you to "interrogate" the site’s data to find specific answers on everything from cures to n=1 observations. Key highlights of the beta launch: Targeted Accuracy:…
Today’s research is moving beyond the traditional "big three" of glucose disposal—liver, muscle, and fat. We explore how red blood cells can be recruited as metabolic "sponges," how AI-driven gut signatures are catching insulin resistance earlier than ever, and why an electronic "cyborg" mesh might be the key to making lab-grown pancreatic cells finally function like the real thing. It’s a steady…
The Type 1 cure is no longer theoretical. Human data now points to a blueprint: working cells, immune evasion, and durable immune modulation. The post Now We Know What a Type 1 Cure Could Look Like first appeared on Diabettech - Diabetes and Technology .